Breaking News, Collaborations & Alliances

AbbVie, Calibr Expand Partnership to Advance Early-Stage Assets

Calibr will present new discovery targets and preclinical assets across immunology, oncology, neuroscience, and other areas of interest.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AbbVie and Calibr expanded their strategic collaboration to advance several innovative preclinical and early-stage assets across AbbVie’s core therapeutic areas including immunology, oncology, neuroscience, and other areas of interest. The partnership with AbbVie and Scripps Research was formed in 2019 to develop a broad range of potential new therapeutics. In addition to programs initially named in the collaboration from preclinical to IND stages of development, Calibr will present a c...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters